| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Long-term operating lease liability | -640 | -420 |
| Net cash used in operating activities | -20,356 | -13,668 |
| Proceeds from issuance of common stock and pre-funded warrants exercise, net of issuance costs | - | 14,364 |
| Proceeds from issuance of common stock, pre-funded warrants exercise, and common warrants exercise, net of issuance costs | 32,703 | - |
| Net cash used in financing activities | 32,703 | 14,364 |
| Increase (decrease) in cash and cash equivalents | 12,347 | 696 |
| Cash and cash equivalents at beginning of period | 8,714 | - |
| Cash and cash equivalents at end of period | 21,061 | - |
Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics Inc. (APVO)